Halozyme Therapeutics (HALO) Competitors $77.57 -0.71 (-0.91%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$77.75 +0.18 (+0.23%) As of 09:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HALO vs. BIIB, UTHR, INCY, NBIX, EXEL, BMRN, EXAS, IONS, MDGL, and RGENShould you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Halozyme Therapeutics vs. Its Competitors Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Ionis Pharmaceuticals Madrigal Pharmaceuticals Repligen Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Do institutionals and insiders believe in HALO or BIIB? 97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.9% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer HALO or BIIB? Halozyme Therapeutics currently has a consensus target price of $69.89, indicating a potential downside of 9.90%. Biogen has a consensus target price of $181.65, indicating a potential upside of 30.40%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Halozyme Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Halozyme Therapeutics 2 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.42Biogen 0 Sell rating(s) 21 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.32 Is HALO or BIIB more profitable? Halozyme Therapeutics has a net margin of 47.28% compared to Biogen's net margin of 15.31%. Halozyme Therapeutics' return on equity of 150.85% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Halozyme Therapeutics47.28% 150.85% 29.19% Biogen 15.31%13.85%8.32% Does the media prefer HALO or BIIB? In the previous week, Biogen had 4 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 28 mentions for Biogen and 24 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.08 beat Biogen's score of 1.04 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 12 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 10 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, HALO or BIIB? Halozyme Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Which has stronger earnings and valuation, HALO or BIIB? Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHalozyme Therapeutics$1.02B8.94$444.09M$4.3717.75Biogen$9.68B2.11$1.63B$10.4613.32 SummaryHalozyme Therapeutics beats Biogen on 11 of the 17 factors compared between the two stocks. Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HALO vs. The Competition Export to ExcelMetricHalozyme TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.16B$3.16B$5.76B$10.50BDividend YieldN/A2.36%5.53%4.58%P/E Ratio17.7521.0476.1826.62Price / Sales8.94252.06471.1091.77Price / Cash16.8346.3537.4661.85Price / Book27.129.7813.776.45Net Income$444.09M-$52.73M$3.29B$271.57M7 Day Performance2.32%3.16%1.84%2.61%1 Month Performance8.01%4.69%4.05%7.28%1 Year Performance38.02%16.37%79.30%29.60% Halozyme Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HALOHalozyme Therapeutics4.5559 of 5 stars$77.57-0.9%$69.89-9.9%+32.5%$9.16B$1.02B17.75390Positive NewsAnalyst ForecastInsider TradeBIIBBiogen4.7309 of 5 stars$143.32-1.1%$181.65+26.7%-28.9%$21.24B$9.68B13.707,605Trending NewsUTHRUnited Therapeutics4.5242 of 5 stars$403.11-0.5%$438.85+8.9%+22.1%$18.27B$2.88B15.731,305Insider TradeINCYIncyte4.7613 of 5 stars$83.14+0.0%$82.53-0.7%+31.8%$16.23B$4.24B18.902,617Positive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.4555 of 5 stars$140.44-1.0%$160.00+13.9%+24.3%$14.07B$2.36B41.551,800Positive NewsAnalyst ForecastEXELExelixis4.6648 of 5 stars$39.01-0.4%$44.06+12.9%+51.0%$10.54B$2.17B18.751,147Positive NewsBMRNBioMarin Pharmaceutical4.9638 of 5 stars$53.14-1.8%$92.04+73.2%-22.7%$10.39B$2.85B15.773,040Positive NewsEXASExact Sciences4.7818 of 5 stars$53.43-0.9%$68.05+27.4%-24.7%$10.21B$2.76B-9.847,000IONSIonis Pharmaceuticals4.0904 of 5 stars$61.10-3.3%$67.88+11.1%+49.6%$10.07B$705M-33.211,069Trending NewsAnalyst ForecastMDGLMadrigal Pharmaceuticals3.901 of 5 stars$425.60-1.5%$483.38+13.6%+96.4%$9.60B$180.13M-33.1290RGENRepligen4.8801 of 5 stars$113.74+0.2%$166.67+46.5%-11.7%$6.39B$634.44M-454.941,778Analyst Upgrade Related Companies and Tools Related Companies BIIB Competitors UTHR Competitors INCY Competitors NBIX Competitors EXEL Competitors BMRN Competitors EXAS Competitors IONS Competitors MDGL Competitors RGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HALO) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
